cobas® SARS-CoV-2

Fast trusted SARS-CoV-2 PCR results, to enable informed care decisions

cobas® SARS-CoV-2
Help prevent the silent spread of SARS-CoV-2

SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.

 

With more than 4.5 million deaths and over 218 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.

 

cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.

 

cobas® SARS-CoV-2:

  • Screen asymptomatic individuals in 20 minutes to help prevent the silent spread of SARS-CoV-2
  • Mobilize fast testing at your priority points of care for greater access for patients
  • Broad strain coverage of SARS-CoV-2 variants for further reassurance with care decisions

 

The cobas® SARS-CoV-2 assay runs on the cobas® Liat® System. A growing menu of molecular POC assays, together with this innovative analyzer, and the connectivity of cobas® infinity POC solution, forms the Roche total point-of-care PCR solution. Now, emergency rooms, primary care and other novel POC settings can reliably standardize and mobilize molecular testing, enhancing patient safety and satisfaction.

Nurse using the cobas Liat system

 

cobas® SARS-CoV-2 Performance*

 

Symptomatic individuals

 

LOD: 1.2 x 10-2 TCID 50/mL

Positive Agreement**

Symptomatic Positive 96.1

(95% CI: 89.0%-98.6%)

Negative Agreement**

Symptomatic Negative 96.8

(95% CI: 92.6%-98.6%)

Asymptomatic individuals


LOD: 1.2 x 10-2 TCID 50/mL

Positive Agreement**

Asymptomatic Positive 100

(95% CI: 84.5%-100%)

Negative Agreement**

Asymptomatic Negative 98.9

(95% CI: 96.2%-99.7%)

* cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System, Package Insert V01, Pleasanton, CA; Roche Molecular Systems, Inc., 2021.
** Compared to FDA EUA SARS-CoV-2 RT-PCR assays; IFU data.   
CI=confidence intervals. LOD=limit of detection.  TCID=tissue culture infective dose.

Learn more about the expanding menus of assays

 
 
 
cobas® Liat® System

 

Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Learn more
Drag Image to Rotate
360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list
Intended Use

Intended Use

The cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of SARS-CoV-2 in self-collected nasal swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal and nasal swabs from either individual suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider or from individuals without symptoms or other reasons to suspect COVID-19.

 

cobas® SARS-CoV-2 is intended for use in the detection of SARS-CoV-2 in clinical specimens. SARS-CoV-2 viral RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection but do not rule out co‑infection with other pathogens not detected by the test. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

 

Negative results do not preclude infection from SARS-CoV-2 and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

 

cobas® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas® Liat® System at the point of care (POC) or in a clinical laboratory setting.

The cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of nucleic acid from SARS-CoV-2 in self-collected anterior nasal (nasal) swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal, mid-turbinate and anterior nasal (nasal) swabs from either individuals suspected of COVID-19 by their healthcare provider or from any individual, including individuals without symptoms or other reasons to suspect COVID-19.


Results are for the identification of SARS-CoV-2 nucleic acids. SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out bacterial infection or co-infection with other viruses. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.


Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.


cobas® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas Liat System.


In the United States (US), testing with cobas® SARS-CoV-2 is authorized for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests. cobas® SARS-CoV-2 is also authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.


Laboratories within the U.S. and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities.


In the U.S., cobas® SARS-CoV-2 is only for use under the Food and Drug Administration’s Emergency Use Authorization."

CE-IVD, FDA Emergency Use Authorization (EUA)

The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Access package inserts through your country’s Roche Diagnostics Website.

young girls diagnosed with influenza

Test for it. Don’t ignore it.

Respiratory

Respiratory tract infections

The non-specific clinical presentation of respiratory infections poses a considerable challenge to the differential diagnosis of pathogens. What impact can a timely and accurate diagnosis have on patient management?

Learn more
Healthcare associated infections

Healthcare-associated infections (HAIs)

From prolonging institutional stays to creating long-term disability, healthcare-associated infections place a tremendous financial burden on health systems.

Learn more
Antimicrobial resistance

Antibiotic resistance and diagnostic testing

In the battle between bacteria and humans, bacteria seem to have the upper hand.

Learn more

References

1. https://covid19.who.int, accessed 3 Sept 2021

cobas® SARS-CoV-2 assay specifications

  • Instrument

    cobas® Liat® Analyser

  • Target

    SARS-CoV-2

  • Sample type

    Nasopharyngeal swab, nasal swab

  • Collection media

    Universal Transport Media (UTM), 0.85 & 0.9% saline

  • Sample extraction

    Fully automated and integrated

  • Technology

    Real-time PCR

  • Control

    Internal sample processing control, positive and negative controls

  • Time to result

    ~20 minutes

  • Reagents

    Ready-to-use, pre-packed tube format

  • Kit Storage

    2-8°C

  • Registration

    Emergency Use Authorization (EUA); CE-IVD